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Abstract  
Objectives 
To establish if athletic cardiac remodelling assessed by cardiovascular magnetic resonance 
(CMR) is mediated by changes in intracellular or extracellular compartments, and whether this 
occurs by one or three months of detraining. 
Background 
Athletic cardiac remodelling can occasionally be difficult to differentiate from pathological 
hypertrophy. Detraining is a commonly used diagnostic test to identify physiological 
hypertrophy which can be diagnosed if hypertrophy regresses. 
Methods  
Twenty-eight athletes about to embark on a period of forced detraining due to incidental limb 
bone fracture underwent clinical assessment, electrocardiogram and contrast enhanced CMR 
within a week of their injury, and then one month and three months later.  
Results  
After one month of detraining there was reduction in left ventricle (LV) mass (130±28g to 
121±25g, P<0.0001), increase in native T1 (1225±30ms to 1239±30ms, P=0.02) and 
extracellular volume fraction (ECV, 24.5±2.3% to 26.0±2.6%, P=0.0007) with no further 
changes by three months. The decrease in LV mass was mediated by a decrease in intracellular 
compartment volume (94±22ml to 85±19ml, P<0.0001) with no significant change in the 
extracellular compartment volume.  
High LV mass index, low native T1 and low ECV at baseline were all predictive of regression 
in LV mass in the first month.  
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Conclusions  
Regression of athletic LV hypertrophy can be detected after just one month of complete 
detraining and is mediated by a decrease in the intracellular myocardial compartment with no 
change in the extracellular compartment. Further studies are needed in athletes with overt and 
pathological hypertrophy to establish if native T1 and ECV may complement 
electrocardiography, echocardiography, cardiopulmonary exercise testing and genetic testing 
in predicting the outcome of detraining. 
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Commentary 1 
Regular athletic training leads to physiological cardiac adaptation, namely biventricular 2 
GLODWDWLRQDQGOHIWYHQWULFOHK\SHUWURSK\VRPHWLPHVWHUPHG³DWKOHWH¶VKHDUW´ Cross-sectional 3 
studies using cardiovascular magnetic resonance T1 mapping imply that athletic left ventricle 4 
hypertrophy is mediated by an increase in the intracellular compartment (predominantly 5 
myocytes), with a relatively constant extracellular compartment (extracellular matrix and 6 
capillary vasculature).  7 
We studied athletes who were about to embark on a period of forced detraining due to incidental 8 
limb bone fracture within a week of their injury, and then one month and three months later. 9 
On complete detraining athletic left ventricle hypertrophy regressed within a month, which was 10 
mediated by decrease in the size of the cellular compartment with no change in the extracellular 11 
compartment.  12 
T1 mapping is a powerful tool to investigate mechanisms and reversibility of hypertrophy in 13 
athletes and may have a role in predicting the outcome of detraining. However, it remains to 14 
be validated in athletes with abnormal ECG and suspected cardiomyopathy.   15 
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Introduction 1 
The regular training that is required to participate in competitive sport leads to physiological 2 
cardiac adaptation, namely biventricular dilatation and left ventricle (LV) hypertrophy, 3 
VRPHWLPHVWHUPHG³DWKOHWH¶VKHDUW´1 LV hypertrophy that overlaps into the pathological range 4 
is relatively rare although does occur more commonly in participants of certain sports such as 5 
rowing and cycling, and in male and black athletes. 2 6 
Cardiovascular magnetic resonance (CMR) is commonly used in the assessment of athletes 7 
with LV hypertrophy as it allows both visualisation of the LV in multiple imaging planes and 8 
detection of focal scar by late gadolinium enhancement imaging (LGE).  T1 mapping by CMR 9 
has been proposed to investigate cardiac tissue characteristics in athletes. Athletes have lower 10 
cardiac extracellular volume fraction (ECV) than sedentary controls and the fittest athletes have 11 
the lowest ECV. 3, 4 These cross-sectional findings imply that athletic LV hypertrophy is 12 
mediated by an increase in the intracellular compartment (predominantly myocytes), with a 13 
relatively constant extracellular compartment (extracellular matrix and capillary vasculature). 14 
Conversely, areas of hypertrophy in hypertrophic cardiomyopathy have increased ECV and 15 
initial data suggests that this divergent pattern might be useful WRGLIIHUHQWLDWHLWIURPDWKOHWH¶V16 
heart. 5   17 
Neither native T1 or ECV has been validated histologically in athletic hypertrophy. However 18 
pUHFOLQLFDOPRGHOVRIDWKOHWH¶Vheart have shown that increase in LV mass in exercise trained 19 
rats is not associated with increase in collagen fraction, therefore implying it is mediated by 20 
increase in myocyte mass. 6, 7 21 
Detraining is a commonly used test to diagnose athletic remodelling, although data supporting 22 
its use are limited. After long term cessation of training regression of hypertrophy and dilatation 23 
occurs in 80% of athletes with cardiac dimensions outside the normal range. 8 A minimum of 24 
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three months detraining is typically required to demonstrate regression of LV hypertrophy 1 
albeit with reduction in training rather than complete cessation. 9, 10 Compliance with detraining 2 
is often poor and it is unpopular with athletes of all level.  There is therefore a need to improve 3 
WKH LGHQWLILFDWLRQ RI DWKOHWH¶V KHDUW E\ QRQ-invasive imaging and predict the outcome of 4 
detraining.  5 
We hypothesised that in athletes who completely stop all forms of training, regression of LV 6 
hypertrophy occurs in one month and is mediated by a decrease in intracellular compartment 7 
volume. We aimed to investigate whether T1 mapping findings at baseline are predictive of the 8 
cardiac consequences of detraining.  9 
Methods 10 
The data that support the findings of this study are available from the corresponding author 11 
upon reasonable request. We prospectively recruited athletes presenting to the emergency 12 
department in Leeds Teaching Hospitals NHS Trust with a limb bone fracture for which they 13 
were advised to stop training for a minimum of six weeks. Only athletes age 18-45 were 14 
included and had to be training for >4 hours a week for >2 years to participate. Exclusion 15 
criteria were any significant past medical history, any regular medication or self-reported use 16 
of anabolic steroids. Some athletes were able to recommence light training (fewer hours and 17 
lower intensity than pre-injury levels) prior to their three month appointment and this was not 18 
prohibited by the research team. The study was approved by the National Research Ethics 19 
Service (16/EM/0399) and all participants gave written informed consent. 20 
Appointments occurred within a week of the injury, one month and three months later. At each 21 
appointment athletes underwent clinical assessment, contrast enhanced CMR and 12 lead 22 
electrocardiogram (ECG). 12 lead ECG (MAC500, GE Medical Systems, Milwaukee, WI, 23 
USA) was analysed by 2 physicians blinded to clinical details according to international 24 
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guidelines for ECG interpretation in athletes. 11  LV mass was estimated from ECG by the 1 
Sokolow-Lyon product, the voltage sum of the greatest S wave in V1/2 and R wave in V5/6. 12 2 
A full blood count, for measurement of haematocrit, was taken at the time of intravenous 3 
cannulation prior to each CMR study.  4 
Cardiovascular Magnetic Resonance Acquisition 5 
Participants underwent CMR on a dedicated cardiovascular 3 Tesla Philips Achieva system 6 
equipped with a 32 channel coil and MultiTransmit® technology. Data were acquired during 7 
breath-holding at end expiration. Balanced steady state free precession (SSFP) cine images 8 
covering the entire heart in the LV short axis were acquired prior to contrast administration 9 
(repetition time (TR) 2.7ms, echo time (TE) 1.3ms, matrix 320 x 320, slice thickness 10mm 10 
with no gap, 30 cardiac phases).  11 
T1 maps were acquired in a three short axis slices. Native T1 mapping used a breath-held 12 
Modified Look-Locker Inversion recovery (MOLLI) acquisition (ECG triggered 5s(3s)3s, 13 
single-shot, SENSE factor 2, prepulse delay 350ms, trigger delay set for end-diastole 14 
(adaptive), flip angle 20°, matrix 400 x 400, slice thickness 10mm, giving a reconstructed voxel 15 
size of 1.17 x 1.17mm). 16 
0.15 mmol/kg of gadobutrol was administered through an intravenous cannula with a 10ml 17 
saline flush (Gadovist®, Bayer Pharma, Berlin, Germany).  18 
Tissue tagging by spatial modulation of magnetization (SPAMM) (spatial resolution 19 
(?î(?(?î(?PPWDJVHSDUDWLRQPPSKDVHV75PV7(PVIOLSDQJOH20 
typical temporal resolution 55 ms) was acquired in the three short axis slices. 13 21 
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Late gadolinium enhancement (LGE) in matching LV short axis planes were carried out more 1 
than 6 minutes after contrast administration. Typical parameters were TR 3.7ms, TE 2.0ms, 2 
flip angle 25o, matrix 512 x 512, slice thickness 8mm with 2mm gap. 3 
Post contrast T1 mapping was carried out exactly 15 minutes following last contrast injection 4 
using 4s(3s)3s(3s)2s MOLLI acquisition with identical positioning and planning to the native 5 
T1 map.  6 
Cardiovascular Magnetic Resonance Analysis 7 
CMR data were assessed quantitatively using commercially available software blinded to 8 
detraining status (CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada). Epicardial and 9 
endocardial borders were traced offline on the short axis cine stack at end-diastole and end-10 
systole to calculate LV and right ventricle (RV) end-diastolic volume (EDV), end- systolic 11 
volume (ESV), stroke volume (SV), ejection fraction (EF) and LV mass. Papillary muscles 12 
were excluded from all measurements. Indexed cardiac parameters were divided by body 13 
surface area calculated by the Mosteller equation at baseline. 14 LGE imaging was analysed 14 
visually to assess for the presence of scarring.   15 
Pre and post contrast myocardial T1 values with a 3-parameter exponential fit with Look-16 
Locker correction were measured from short axis slices in the septum.Average measurements 17 
from the basal and mid ventricular slices were used. Data from the apical slice was not used 18 
because it was vulnerable to partial volume effects due to decreased wall thickness. ECV was 19 
calculated from native and post contrast T1 times of myocardium and blood pool and 20 
haematocrit as previously reported. 15  21 
Intracellular compartment volume was calculated by multiplying (1-ECV) x (LV mass/1.05).  22 
Extracellular compartment volume was calculated by multiplying ECV x (LV mass/1.05). 16 23 
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Tagging analysis was conducted using inTag (v1.0 CREATIS lab, Lyon, France). Endocardial 1 
and epicardial contours were drawn on the short axis SPAMM sequences using a semi-2 
automated process as reported previously. 13 Peak LV circumferential strain was measured for 3 
the three slices.   4 
Statistical analysis and power calculation  5 
Statistical analysis was performed using IBM SPSS® Statistics 22.0 (IBM Corp., Armonk, 6 
NY). Continuous variables were expressed as mean ± SD or median (interquartile range) 7 
depending upon normality. Categorical variables were expressed as N (%). Paired data at 8 
baseline one and one month were compared by paired t test. When comparing three paired 9 
groups, analysis of variance (ANOVA) with repeated measures was used.  P<0.05 was 10 
considered statistically significant. 11 
Receiver operating characteristic analysis was used to determine the diagnostic accuracy 12 
baseline imaging parameters to predict regression of left ventricular hypertrophy (>10g) or 13 
cavity dilatation (>10ml). The diagnostic accuracy is expressed as area under the curve (AUC) 14 
and 95% confidence interval. Optimal sensitivity and specificity were calculated using Youden 15 
index. Variables were combined by binary logistic regression. AUCs were compared by using 16 
validated methods described by DeLong et al 17.   17 
The study was powered to detect a 7.5% decrease in indexed intracellular compartment volume 18 
after one month of detraining. Assuming that baseline indexed intracellular compartment 19 
volume would be comparable to low performance athletes in our previous study, which was 20 
47±6ml/m2 a minimum sample size of 25 athletes would be required SRZHU Į . 3 21 
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Results 1 
Thirty-five athletes agreed to take part in the study between November 2016 and March 2018. 2 
One athlete was unable to complete the study because of claustrophobia, one withdrew because 3 
of possible pregnancy and five withdrew consent after the first scan but before the second scan. 4 
The final cohort of 28, included 23 male and 5 female athletes with a median age of 24 (IQR: 5 
21 - 30) years. Twenty-three athletes completed the whole protocol, with five athletes 6 
withdrawing after their one month scan because they had resumed full training. Baseline 7 
characteristics and their progression throughout the study are shown in Table 1. There were 31 8 
± 5 days between the baseline and one month scan, and 94 ± 10 days between the baseline and 9 
three month scans. Athletes trained in a wide range of sports including soccer 9, rugby 5, 10 
running 4, mixed sports 4, cycling 3, hockey 1, netball 1 and triathlon 1. Prior to their injury 11 
athletes trained median 7 hours per week (IQR 5-9). 12 
Changes in Surface Electrocardiogram 13 
On one month detraining there was a significant decrease in the voltage of the R wave in chest 14 
lead V5 and the Sokolow-Lyon product, both electrical markers of left ventricular mass, Table 15 
2. There were no significant changes in heart rate, PR interval or QTc. 16 
Changes in Ventricular Morphology 17 
After one month of complete detraining there was a 9.3g (7%, P<0.0001) reduction in LV mass 18 
with no further reduction between one and three months, Figure 1 and Table 3. This remained 19 
significant when indexed to baseline body surface area. In the first month there were significant 20 
increases in native T1 and ECV, Figure 2. There was a decrease in intracellular compartment 21 
volume (8.4ml, 9%, P<0.0001) with no significant change in the extracellular compartment 22 
mass, Figure 3. 23 
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After one month of complete detraining there were significant comparable decreases in the end 1 
diastolic volumes of both ventricles (¨LV -8.2ml, -4.3%, P=0.003; ¨RV -7.8ml, -4.1%, 2 
P=0.03).  By three months of detraining there was no further decrease in end diastolic volume 3 
of either ventricle, Table 3. There was no difference in these temporal changes when they were 4 
indexed to baseline body surface area. There was no significant change in LV EF throughout 5 
detraining, but there was a reduction in RV EF after one month due to decreased RV EDV.  6 
No athlete had scarring detected on LGE imaging on any scan.  7 
After one month of detraining there were non-significant absolute increases in peak 8 
circumferential strain all three levels (¨apex 0.4%, P=0.61¨PLG/93 0.30¨EDVH9 
1.4% P=0.06). There were no further changes at three months.  10 
Comparison of those who had and who had not resumed training.  11 
Between the one month and three month scan 11/23 athletes were able to restart light training, 12 
but were still not able to resume full training. When athletes were split according to those who 13 
had resumed light training (N=11) and those who had not (N=12) there was no difference in 14 
any LV or RV volumetric parameter, native T1 or ECV, Supplementary Table 1. 15 
Baseline parameters to predict cardiac regression 16 
High LV mass index, low native T1 and low ECV at baseline were all predictive of an absolute 17 
LV mass regression in one month of detraining of more than 10g (P=0.0006, 0.04 and 0.03 18 
respectively) Supplementary Table 2. The difference in diagnostic accuracy between LV 19 
mass index and native T1 (P=0.58) or ECV (P=0.71) was not significant. When LV mass index 20 
was combined with either native T1 or ECV by a binary logistic model there was an 21 
improvement in diagnostic accuracy, Supplementary Table 2. None of LV EDV index, native 22 
T1 or ECV were predictive of absolute LV EDV regression in one month of detraining of more 23 
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than 10ml. Only RV EDV index, but not native T1 or ECV, were predictive of absolute RV 1 
EDV regression in one month of detraining of more than 10ml.  2 
Discussion 3 
We have shown that in athletes after just one month of complete detraining there is regression 4 
of LV mass, LV EDV and RV EDV. There was no further regression of any measure by three 5 
months of detraining. The regression of LV mass is mediated by a decrease in intracellular 6 
compartment volume (predominantly cardiac myocytes) with no change in extracellular 7 
compartment volume. High baseline LV mass is the strongest predictor of regression of LV 8 
hypertrophy after one month of detraining. Low native T1/ECV were also predictive of LV 9 
mass regression at one month and may have a role in the diagnoVLVRIDWKOHWH¶VKHDUW 10 
Insights into the mechanisms of athletic ventricular remodelling 11 
We have demonstrated that regression in LV mass is mediated by a decrease in the intracellular 12 
myocardial compartment with no change in the size of extracellular compartment. Previous 13 
studies have demonstrated that athletes have lower ECV than sedentary controls and that the 14 
fittest athletes have the lowest ECV. 3, 4 These studies were cross-sectional and therefore cannot 15 
be used to attribute causality. Our present study is the first to show a longitudinal relationship 16 
between LV mass, ECV and training, confirming the hypothesis that athletic hypertrophy is 17 
mediated by an increase in the cellular compartment. 18 
When T1 mapping data and LV mass are combined it is possible to dichotomise the 19 
myocardium into cellular and extracellular compartments. This pattern is particularly relevant 20 
in hypertrophic phenotypes and has been validated most comprehensively in aortic stenosis 21 
where the derived extracellular compartment volume has a strong correlation with diffuse 22 
fibrosis on biopsy 18 and there is regression of both the cellular and extracellular compartments 23 
after aortic valve replacement. 16 24 
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The most important differential diagnosis in the young athlete with LV hypertrophy is 1 
hypertrophic cardiomyopathy. CMR tissue characterisation has been histologically validated 2 
in hypertrophic cardiomyopathy and can be used to detect both diffuse fibrosis (increased ECV) 3 
and replacement fibrosis (focal LGE). 19, 20 High level athletes with hypertrophic 4 
cardiomyopathy are reported to have an altered phenotype with more prominent cavity 5 
dilatation but replacement fibrosis is still identified in 33%. 21 In hypertrophic cardiomyopathy 6 
focal fibrosis is progressive and the extent of LGE increases progressively over the course of 7 
the disease. 22 Saberi et al performed a study of 113 patients with hypertrophic cardiomyopathy 8 
who were randomised to a 16 week programme of moderate intensity exercise or standard care. 9 
23
 They reported that exercise training led to increased exercise capacity, but did not change 10 
ventricular volumes or the extent of focal fibrosis on LGE.  11 
It would be appealing to conduct a study of detraining in high level athletes with HCM to 12 
investigate reversibility of changes in cellular and extracellular compartments. However, in 13 
practice such a study would be almost impossible given the small number of patients with 14 
hypertrophic cardiomyopathy who participate in competitive sport and their low willingness to 15 
voluntarily detrain.   16 
7 PDSSLQJ LQ DWKOHWH¶V KHDUW KDV QRW EHHQ YDOLGDWHG KLVWRORJLFDOO\ However there are 17 
preclinical rat models of exercise induced cardiac hypertrophy, which suggest physiological 18 
hypertrophy is not mediated by increase in myocardial collagen. 6, 7 Benito et al trained rats to 19 
run on a treadmill for an hour a day. 24 After 8 weeks of training there was an 11% increase in 20 
LV mass, but no alteration in the hydoxyproline (a modified amino-acid found specifically in 21 
collagen) content of the whole left ventricle. These results are in keeping with our finding that 22 
athletic hypertrophy is mediated by preferential expansion of the intracellular compartment.   23 
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Effects of detraining on cardiac morphology 1 
Previous studies have demonstrated that the heart is highly adaptable to physical training and 2 
cross sectional studies have clearly demonstrated a dose response relationship between degree 3 
of fitness (measured quantitatively by cardiopulmonary exercise test) and extent of LV and RV 4 
remodelling.25 Arbab-Zadeh et al demonstrated in a longitudinal study of 12 previously 5 
sedentary subjects when trained for endurance sport development of cardiac athletic 6 
remodelling, albeit to a lesser extent than that seen in elite athletes. 26 They reported that in the 7 
first three months of training there were significant increases in RV EDV and LV mass with 8 
increase in LV EDV by 6 months. Most of the subjects were training for the marathon and it is 9 
not known whether these longitudinal patterns of remodelling apply to other sports or training 10 
regimes. Cardiac hypertrophy regression with detraining in our study was quicker, taking only 11 
one month, compared to remodelling on commencement of training which took at least 3 12 
months in the previous study. 26 Although it should be noted the previous study did not conduct 13 
imaging at one month and participants in both studies conducted different sports with different 14 
baseline fitness.   15 
The evidence of regression of athletic ventricular remodelling with detraining largely predates 16 
CMR and studies were conducted by echocardiography.  Maron et al reported that LV mass 17 
measured by echocardiography in 6 Olympic rowers/canoeists decreased by 75g (24%) in a 18 
voluntary period (mean 13 weeks) of detraining following the 1988 Seoul Olympic Games. 9 19 
Weiner et al reported a significant regression in LV mass of 4 college American Football 20 
players with LV hypertrophy after 3 months of voluntary detraining that returned to pre-21 
training level by 6 months. 10 In a cohort of 40 Olympians Pellicia et al reported a 28% 22 
reduction in LV mass after long term detraining (1-13 years). 8 These studies included athletes 23 
with  LV hypertrophy at baseline (>12mm interventricular septum) and included athletes at the 24 
pinnacle of fitness. The LV hypertrophy was more pronounced in these studies than ours, 25 
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reflecting the fitness of the athletes studied. The extent of LV mass regression was therefore 1 
greater (24-28% vs 7%). These studies defined detraining as reduction in exercise intensity 2 
rather than complete cessation perhaps explaining why regression of LV mass not reported 3 
until three months compared to one month in our study.  4 
Pedlar et al performed echocardiography in 21 amateur runners after an 18 week training 5 
programme and then after 4 and 8 weeks when participants were limited to <2 hours of training 6 
a week. 27 Similarly to our findings they reported a 10.4% reduction in LV mass after 4 weeks 7 
with no change in LV EDV even 8 weeks post-race.   8 
The finding of early regression of LV mass is not unique to athletes, and has been reported in 9 
by CMR in healthy individuals (N=5) after 6 weeks complete voluntary bed rest 28 and by 10 
echocardiography in astronauts (N=38) immediately after a 9-16 day spaceflight. 29  11 
The mean LV mass in the present study (130 ± 28g) was comparable to low performance male 12 
athletes in our previous study (129 ± 17g) who had a mean VO2max of 60 ± 8mls/kg/min. If we 13 
had been able to recruit higher performance athletes with higher LV mass at baseline we may 14 
have been able to detect a further decrease in LV mass between one and three months. An 15 
alternative explanation is that the pattern of regression reflects the nature of detraining. Athletes 16 
were most incapacitated immediately after their fracture leading to most regression in this 17 
period. Throughout the subsequent recovery the levels of physical activity gradually increased 18 
affecting the regression response.  19 
Using the same CMR tagging methodology we have previously shown that athletes have lower 20 
peak circumferential strain than sedentary controls. 13 In the current study, we found that in all 21 
three levels there was a no significant increase in strain on detraining, despite significant 22 
decreases in LV mass and intracellular compartment in the same period.  23 
16 
 
Limitations 1 
In this study we relied upon self-reported abstinence from training and it is therefore possible 2 
that athletes carried out training that was not reported to the research team. We have not 3 
conducted an objective assessment of fitness using cardiopulmonary exercise test but this was 4 
not possible due to the nature of the SDUWLFLSDQWV¶ injuries. Athletes in this study participated in 5 
a range of sports which giving different patterns of athletic remodelling at baseline. We did not 6 
collect data on non-steroidal anti-inflammatory use which may have caused fluid retention and 7 
altered the myocardial extracellular compartment. We have not studied athletes with an 8 
abnormal ECG, overt LV hypertrophy (12-15mm) or cardiomyopathy and patterns of 9 
regression in these groups remains to be established.  10 
T1 mapping has only been validated histologically in disease and is difficult to validate in 11 
DWKOHWH¶VKHDUW1DWLYH7DQGOHVVVR ECV) vary by field strength, manufacturer and pulse 12 
sequence. At present it is recommended that normal values specific to the scanner and 13 
acquisition protocol are used to determine ECV in the athlete with unexplained LV hypertrophy 14 
30
.    15 
Conclusions 16 
Regression of athletic LV hypertrophy can be detected after just one month of complete 17 
detraining and is mediated by a decrease in the intracellular myocardial compartment with no 18 
change in the extracellular compartment. Further studies are needed in athletes with overt and 19 
pathological hypertrophy to establish if native T1 and ECV may complement 20 
electrocardiography, echocardiography, cardiopulmonary exercise testing and genetic testing 21 
in predicting the outcome of detraining.  22 
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Figure 1. Change in cardiac morphology on detraining. Change in left and right ventricular 
end diastolic volume (EDV), ejection fraction (EF) and mass after one and three months 
detraining. 
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Figure 2. Native T1 and ECV (extracellular volume fraction) maps before and after one 
month of detraining. Native T1 (above) and ECV (below) maps from a rugby player before 
and after one month of detraining. Over this period native T1 increased from 1160ms to 
1213ms, ECV increased from 19.5% to 23.3% and LV mass decreased from 186g to 164g. 
Typical myocardial and blood pool contours are shown in the lower left panel.  
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Figure 3. Change in cardiac compartment volumes on complete detraining. Individual 
participant data showing volumes of intracellular (red) and extracellular (blue) compartments 
at baseline and then after one and three months of detraining. 
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Table 1: Clinical characteristics subjects presented as mean ± standard deviation or median (interquartile range) 
 Baseline One month 
detraining 
P value vs 
baseline 
Three months 
detraining 
P value vs 
baseline 
P value vs 1 
month 
N 28 28  23   
Age 24 (21 - 30)      
Male Sex (%) 23 (82) 23 (82)  20 (87)   
Height (cm) 177 ± 8      
Weight (kg) 78 ± 14 77 ± 12 0.21 76 ± 12 1.0 1.0 
Hours per week spent training 7 (5 - 9) 0 (0 - 0) <0.0001 0.5 (0 - 6) <0.0001 0.0001 
Heart Rate 65 ± 10 68 ± 11 0.20 62 ± 9 0.19 0.05 
Systolic Blood Pressure (mmHg) 121 (118 - 131) 122 (114 - 130) 0.39 119 (113 - 124) 0.01 0.17 
Diastolic Blood Pressure (mmHg) 64 (60 - 75) 65 (57 - 72) 0.64 63 (54 - 68) 0.16 0.18 
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Table 2: Electrocardiogram findings 
 Baseline One month 
detraining 
P value vs 
baseline 
Three months 
detraining 
P value vs 
baseline 
P value vs 1 
month 
Heart Rate (bpm) 67 ± 11 70 ± 9 0.17 64 ± 8 0.06 0.05 
PR interval (s) 145 ± 21 148 ±  22 0.13 147 ± 19 0.64 1.0 
QTc inverval (s) 410 ± 19 416 ± 22 0.08 409 ± 21 1.0 0.45 
SV2, mV 14 ± 6 14 ± 6 0.36 14 ± 5 0.52 1.0 
RV5, mV 16 ± 5 14 ± 4 0.006 16 ± 6 1.0 1.0 
Sokolow-Lyon Product, mV 31 ± 8 29 ± 8 0.01 30 ± 7 0.82 0.52 
Incomplete RBBB, n (%) 5 (18) 4 (14)  4 (17)   
T wave inversion, n (%) 1 (4) 1 (4)  0 (0)   
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Table 3: Cardiovascular magnetic resonance findings  
 Baseline One month 
detraining 
P value vs 
baseline 
Three months 
detraining 
P value vs 
baseline 
P value vs 1 
month 
LV EDV (ml) 190 ± 32 182 ± 30 0.003 188 ± 35 1.0 0.38 
LV EDV index (ml/m2) 98 ± 13 94 ± 15 0.007 98 ± 17 1.0 0.34 
LV ESV (ml) 76 ± 17 75 ± 17 0.72 81 ± 21 0.18 0.37 
LV EF (%) 60 ± 5 59 ± 5 0.27 57 ± 5 0.07 0.69 
LV mass (g) 130 ± 28 121 ± 25 <0.0001 121 ± 23 0.0007 1.0 
LV mass index (g/m2) 66 ± 10 62 ± 11 0.0005 63 ± 11 0.02 1.0 
RV EDV (ml) 188 ± 39 181 ± 35 0.03 180 ± 35 0.59 1.0 
RV EDV index (ml/m2) 97 ± 17 93 ± 15 0.02 93 ± 13 0.53 1.0 
RV ESV (ml) 80 ± 18 81 ± 15 0.76 81 ± 19 1.0 1.0 
RV EF (%) 57 ± 6 55 ± 5 0.02 55 ± 7 0.51 1.0 
Native T1 (ms) 1225 ± 30 1239 ±30 0.02 1228 ± 47 1.0 0.79 
ECV (%) 24.5 ± 2.3 26.0 ± 2.6 0.0007 25.6 ± 2.8 0.04 1.0 
Extracellular compartment volume (ml) 30 ± 5 30 ± 5 0.49 29 ± 5 1.0 1.0 
Intracellular Compartment volume (ml) 94 ± 22 85 ± 19 <0.0001 86 ± 18 0.0002 1.0 
Circumferential strain Apex (%) 12.8 ± 4.5 13.2 ± 3.1 0.61 14.0 ± 3.2 0.57 0.32 
Circumferential strain Mid LV (%) 13.4 ± 4.5 14.5 ± 2.7 0.30 14.1 ± 2.3 1.0 1.0 
Circumferential strain Base (%) 13.0 ± 4.1 14.4 ± 2.6 0.06 14.1 ± 2.9 0.45 1.0 
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